Abstract
Considerable evidence indicates that the GABAA receptor is a molecular target for general anesthetics in the CNS. However, most clinical anesthetists are puzzled by this (unifying) observation as the clinical features of anesthesia differ among anesthetics. Central noradrenergic neurons are known to regulate physiological functions including the sleep-wake cycle, motor activity, and autonomic nervous function. These physiological responses are depressed during general anesthesia. In addition, animal experiments have shown that general anesthetics, which activate GABAA receptors, depress brain noradrenergic neurons. Thus, we have focused on this neuronal system as a “wiring” target for general anesthetic action. However, ketamine, nitrous oxide and xenon, which act as NMDA receptor antagonists, markedly increase noradrenaline release in tissues from several brain regions. Consistent with the clinical features of anesthesia modulation of noradrenergic neurons could differ between the type of anesthetic agents. Therefore, loss of consciousness could be produced by cerebral depression but also over-excitation (e.g. convulsion). Sleep is also induced by not only hypothermia (hibernation) but also body heating that activates heat-sensitive neurons in the preoptic area. Wakefulness, that is to say, may maintain within a set range and that when this range is exceeded (above or below), unconsciousness may be induced. Recently we have accumulated several pieces of evidence supporting this hypothesis. In addition, we found that orexins, wakefulness-promoting neuropeptides, predominantly evoke noradrenaline release from rat cerebrocortical slices, and that activation of orexinergic neurons reduces the duration of anesthesia. Thus, noradrenergic and orexinergic neurons may be involved in the mechanism of general anesthesia.
Keywords: noradrenergic, orexinergic neurons, anesthesia, gabaa receptor, ketamine, nmda receptor antagonists
Current Neuropharmacology
Title: Role of Noradrenergic and Orexinergic Neurons in General Anesthesia
Volume: 1 Issue: 4
Author(s): Kazuyoshi Hirota, Tetsuya Kushikata and Mihoko Kudo
Affiliation:
Keywords: noradrenergic, orexinergic neurons, anesthesia, gabaa receptor, ketamine, nmda receptor antagonists
Abstract: Considerable evidence indicates that the GABAA receptor is a molecular target for general anesthetics in the CNS. However, most clinical anesthetists are puzzled by this (unifying) observation as the clinical features of anesthesia differ among anesthetics. Central noradrenergic neurons are known to regulate physiological functions including the sleep-wake cycle, motor activity, and autonomic nervous function. These physiological responses are depressed during general anesthesia. In addition, animal experiments have shown that general anesthetics, which activate GABAA receptors, depress brain noradrenergic neurons. Thus, we have focused on this neuronal system as a “wiring” target for general anesthetic action. However, ketamine, nitrous oxide and xenon, which act as NMDA receptor antagonists, markedly increase noradrenaline release in tissues from several brain regions. Consistent with the clinical features of anesthesia modulation of noradrenergic neurons could differ between the type of anesthetic agents. Therefore, loss of consciousness could be produced by cerebral depression but also over-excitation (e.g. convulsion). Sleep is also induced by not only hypothermia (hibernation) but also body heating that activates heat-sensitive neurons in the preoptic area. Wakefulness, that is to say, may maintain within a set range and that when this range is exceeded (above or below), unconsciousness may be induced. Recently we have accumulated several pieces of evidence supporting this hypothesis. In addition, we found that orexins, wakefulness-promoting neuropeptides, predominantly evoke noradrenaline release from rat cerebrocortical slices, and that activation of orexinergic neurons reduces the duration of anesthesia. Thus, noradrenergic and orexinergic neurons may be involved in the mechanism of general anesthesia.
Export Options
About this article
Cite this article as:
Hirota Kazuyoshi, Kushikata Tetsuya and Kudo Mihoko, Role of Noradrenergic and Orexinergic Neurons in General Anesthesia, Current Neuropharmacology 2003; 1 (4) . https://dx.doi.org/10.2174/1570159033476991
DOI https://dx.doi.org/10.2174/1570159033476991 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
Call for Papers in Thematic Issues
Advances in Neuroinflammation and Neuroprotection: Mechanisms and Therapeutic Frontiers
It offers a comprehensive exploration of neuroinflammatory and neuroprotective pathways that play central roles in a range of neurological disorders, including stroke, traumatic brain injury, and neurodegenerative diseases such as Alzheimer’s and Parkinson’s. This issue invites research on the cellular and molecular mechanisms driving neuroinflammation, such as the roles of ...read more
Advances in paediatric and adult brain cancers: emerging targets and treatments
Brain tumors are the most common solid tumors affecting children and adolescents, with up to 5,000 children diagnosed per year. Pediatric brain tumors, because of their location, are often untreatable and their clinical management can cause significant long-term impairment to intellectual and neurological function with epilepsy and neurodegeneration. Other than ...read more
Emotion (Dys)regulation: An integration of Pharmacological, Neurobiological, and Psychological Frameworks
Emotion regulation is a critical aspect of mental well-being and interpersonal relationships. To fully understand and effectively address emotion regulation, an integrative approach that considers pharmacological, neurobiological, and psychological frameworks is essential. Pharmacological interventions, such as medications targeting neurotransmitter imbalances, can play a significant role in managing emotional dysregulation. Understanding ...read more
Intercellular Communications in Cerebral Ischemia
Cerebral ischemia, a condition in which there is inadequate blood supply to the brain, ranks as one of the leading causes of disability and mortality globally. Despite its prevalence and severity, efficacious treatment options for this debilitating disorder remain limited. Recent scientific explorations have delved deeply into the pathological mechanisms ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
GABAergic Modulation in Diabetic Encephalopathy-Related Depression
Current Pharmaceutical Design A Retrospective, Multi-Center Cohort Study Evaluating the Severity- Related Effects of Cerebrolysin Treatment on Clinical Outcomes in Traumatic Brain Injury
CNS & Neurological Disorders - Drug Targets Conotoxins and Structural Biology: A Prospective Paradigm for Drug Discovery
Current Protein & Peptide Science Prospective Function of Different Antioxidant Containing Natural Products in the Treatment of Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Insights into the Drug Repositioning Applied to the Alzheimer's Disease Treatment and Future Perspectives
Current Alzheimer Research The Progress of Epilepsy after Stroke
Current Neuropharmacology MicroRNA-34a and its target genes: Key factors in cancer multidrug resistance
Current Pharmaceutical Design A Review of <i>Saurauia roxburghii</i> Wall. (Actinidiacaea) as a Traditional Medicinal Plant, Its Phytochemical Study and Therapeutic Potential
Mini-Reviews in Medicinal Chemistry Inflammation and Neurogenesis in Temporal Lobe Epilepsy
Current Drug Targets - CNS & Neurological Disorders Chvostek's Sign in Paediatric Practice
Current Pediatric Reviews Clinical and Electroencephalographic Assessment of Cefepime During Treatment of Nosocomial Infections in Neurological Patients
Central Nervous System Agents in Medicinal Chemistry Drug Repurposing: An Emerging Tool for Drug Reuse, Recycling and Discovery
Current Drug Research Reviews Disruption of Zinc Neuromodulation by Aß Oligomers : Therapeutic Implications
Current Pharmaceutical Design Astrocytes: New Targets for the Treatment of Neurodegenerative Diseases
Current Pharmaceutical Design Gene Therapy for Angelman Syndrome: Contemporary Approaches and Future Endeavors
Current Gene Therapy Dopamine: Agonists and Neurodegenerative Disorders
Current Drug Targets GH-Inhibitory Activity of Novel Somatostatin Agonists: Potential Applications in Acromegaly
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents HIV-1, Methamphetamine and Astrocyte Glutamate Regulation: Combined Excitotoxic Implications for Neuro-AIDS
Current HIV Research Prader-Willi Syndrome: Genetics, Phenotype, and Management
Current Psychiatry Reviews Recent Advances of Fluorescent Technologies for Drug Discovery and Development
Current Pharmaceutical Design